Overview

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Prader-Willi Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Neuren Pharmaceuticals Limited